Biosplice Doses First Patient in AML/MDS Clinical Trial
Biosplice has initiated dosing in an NCI-sponsored Phase 1 study of cirtuvivint in relapsed/refractory AML and MDS, testing the...
eClinical Tech News
Maze’s MZE782 Shows Positive Results for PKU, CKD in Trial
In a randomized, placebo-controlled Phase 1 study in 112 healthy adults, Maze’s SLC6A19 inhibitor MZE782 produced large, dose-dependent pharmacodynamic...
New Dubstent Trial Seeks Better PCI Outcomes for Diabetes
A 120-patient randomized trial in Ireland will compare a hybrid percutaneous coronary intervention strategy—drug-coated balloon angioplasty followed by drug-eluting...
First Patient Dosed in New Glioblastoma/Pancreatic Study
RadioMedix and Vect-Horus have dosed the first patient in an exploratory IND evaluating 203Pb-RMX-VH-PIB, an LDL receptor–targeted SPECT imaging...
Vaxart Reports Positive Phase 1 Data for Norovirus Pill
Vaxart’s second-generation oral norovirus constructs drove a 25-fold increase in GII.4 fecal IgA and a 10-fold increase in GI.1...
New daraxorasib Data Supports Phase 3 Pancreatic Cancer Trial
In second-line metastatic PDAC, daraxonrasib monotherapy at 300 mg QD delivered a confirmed ORR of 35% in KRAS G12X...
Trethera Completes Enrollment for Phase 1 Solid Tumor Trial
Dose escalation with oral TRE-515 has reached 1,440 mg once daily—36-fold above the starting dose of 40 mg—without dose-limiting...
Encaleret Normalizes Calcium in Phase 2 Hypoparathyroidism
In a 10-patient Phase 2 proof-of-concept study in post-surgical hypoparathyroidism, 80% of participants on encaleret achieved concomitant normalization of...
Junshi’s Psoriasis Drug JS005 Succeeds in Phase 3 Trial
Junshi Biosciences reported that its anti–IL-17A monoclonal antibody JS005 met both co-primary endpoints—PASI 90 and sPGA 0/1 at Week...
Rapport to Announce RAP-219 Phase 2a Seizure Trial Results
Rapport Therapeutics will release topline results from its Phase 2a study of RAP-219 in drug-resistant focal onset seizures on...